Orexo starts to test modia on patients in collaboration with ApexB.io and Magellan Rx Management
1
- The medication-assisted treatment (MAT) of opioid use disorder (OUD) requires a combination of drug and therapy treatment, where access and quality of counselling and psychosocial support are one of the main barriers to successful treatment
- modia can help those with OUD by providing access to an evidence-based digital therapy rooted in cognitive behavioral techniques
UPPSALA, Sweden, Feb. 10, 2021 /PRNewswire/ Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the company will collaborate with ApexB.io and Magellan Rx Management to further research on the use of modia, a digital therapeutic designed for individuals with opioid use disorder (OUD), by establishing a novel, real-world evidence approach. modia, offers individuals with OUD access to tailored, interactive psychotherapy interventions through their mobile device or computer.
Orexo calls for redemption of its outstanding bonds and obtains temporary waiver
News provided by
Share this article
(STO:ORX) (OTCQX:ORXOY) ) has today given notice to all holders of the Company s maximum SEK 500,000,000 senior unsecured callable floating rate bonds 2017/2021 with ISIN SE0010494450 (the Bonds ) of exercise of its option for early redemption of the Bonds in full.
The date for the redemption will fall on 3 March 2021 ( Redemption Date ) and the record date for the redemption will fall on 24 February 2021 ( Record Date ).
The Bonds will be irrevocably redeemed on the redemption date at a redemption price corresponding to 101.50 percent of the total outstanding nominal amount (
Orexo has successfully issued senior unsecured callable floating rate bonds
News provided by
Share this article
UPPSALA, Sweden, Feb. 4, 2021 /PRNewswire/ Orexo AB (publ.), ( Orexo or the Company )
(STO:ORX) (OTCQX:ORXOY) has successfully issued senior unsecured callable floating rate bonds in the amount of SEK 500 million, under a framework of SEK 1,000 million with final maturity in February 2025 (the New Bonds ). The New Bonds carry a floating rate interest of 3-month Stibor + 375bps per annum. The issue was well oversubscribed and received strong interest from both Nordic and international institutional investors.
As a result of the issue of the New Bonds, the Company will repurchase SEK 77.4 million of its outstanding senior unsecured callable floating rate bonds (ISIN: SE0010494450) (the Existing Bonds ). The Company will call for early redemption of the residual amount of the Existing Bonds, SEK 148.5 million, in accordance with the terms and conditions of the Exis
Orexo expects FDA filing of OX124 mid 2022
- OX124 is designed to reverse the effect of the most powerful synthetic opioids
- Synthetic opioids are behind the majority of fatal overdoses in the US, a development expected to increase due to Covid-19
- New Drug Application (NDA) filing expected mid 2022
UPPSALA, Sweden, Jan. 29, 2021 /PRNewswire/ Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that it is expecting to file its flagship pharmaceutical pipeline asset OX124 with the US Food and Drug Administration mid-2022. OX124 is expected to follow the FDA s standard submission and review timelines, as the FDA did not grant Fast Track Designation to the product. Given the medical need to swiftly make powerful rescue medications available to those in need, Orexo will continue to work closely with the FDA to expedite the route to approval. The FDA s decision is not related to the product, but is based on an overall assessment whether the development program meets the s